Axsome Therapeutics Temettüler ve Geri Alımlar

Temettü kriter kontrolleri 0/6

Axsome Therapeutics şirketinin temettü ödeme geçmişi bulunmamaktadır.

Anahtar bilgiler

n/a

Temettü verimi

-1.3%

Geri Alım Getirisi

Toplam Hissedar Getirisi	-1.3%
Gelecekteki Temettü Verimi	0%
Temettü Büyümesi	n/a
Bir sonraki temettü ödeme tarihi	n/a
Eski temettü tarihi	n/a
Hisse başına temettü	n/a
Ödeme oranı	n/a

Son temettü ve geri alım güncellemeleri

Güncelleme yok

Recent updates

Axsome Therapeutics, Inc. (NASDAQ:AXSM) First-Quarter Results: Here's What Analysts Are Forecasting For This Year

May 09

Axsome Therapeutics, Inc.'s (NASDAQ:AXSM) Price In Tune With Revenues

Apr 13

Does Axsome Therapeutics (NASDAQ:AXSM) Have A Healthy Balance Sheet?

Mar 17

Axsome: Unpacking Auvelity's First-Year Market Dynamics And Economic Challenges

Feb 21

Axsome Therapeutics, Inc.'s (NASDAQ:AXSM) P/S Is Still On The Mark Following 27% Share Price Bounce

Dec 27

Is Axsome Therapeutics (NASDAQ:AXSM) Using Debt In A Risky Way?

Dec 12

Is Axsome Therapeutics (NASDAQ:AXSM) Using Debt In A Risky Way?

Sep 12

Axsome Therapeutics, Inc.'s (NASDAQ:AXSM) Price In Tune With Revenues

Aug 08

Upgrade: Analysts Just Made A Dazzling Increase To Their Axsome Therapeutics, Inc. (NASDAQ:AXSM) Forecasts

May 13

Earnings Update: Axsome Therapeutics, Inc. (NASDAQ:AXSM) Just Reported Its Yearly Results And Analysts Are Updating Their Forecasts

Mar 03

Is Axsome Therapeutics (NASDAQ:AXSM) Using Debt Sensibly?

Mar 01

Is Axsome Therapeutics (NASDAQ:AXSM) Weighed On By Its Debt Load?

Nov 14

Axsome Therapeutics: Clear Path Ahead For AXS07

Oct 05

Axsome to resubmit marketing application for migraine therapy in Q3 2023

Sep 29

Axsome: In The Middle Of Uncertainty Is Your Biggest Opportunity

Sep 16

Axsome begins enrolling in late-stage study of migraine drug AXS-07

Sep 01

Axsome gains 19% as FDA approves depression therapy

Aug 19

Axsome Therapeutics Q2 2022 Earnings Preview

Aug 08

Axsome: Breaking Bearish Trend

Jul 26

Axsome: One Step At A Time

Jul 01

Axsome And AXS-05: A Special Situation

May 02

Ödemelerde İstikrar ve Büyüme

Temettü verilerini getirme

İstikrarlı Temettü: AXSM şirketinin hisse başına düşen temettülerinin geçmişte istikrarlı olup olmadığını belirlemek için yeterli veri yok.

Büyüyen Temettü: AXSM şirketinin temettü ödemelerinin artıp artmadığını belirlemek için yeterli veri yok.

Piyasaya Karşı Temettü Getirisi

Axsome Therapeutics Piyasaya Karşı Temettü Getirisi

AXSM temettü verimi piyasa ile karşılaştırıldığında nasıldır?
Segment	Temettü Verimi
Şirket (AXSM)	n/a
Pazarın Alt %25'i (US)	1.4%
Pazarın En İyi %25'i (US)	4.3%
Sektör Ortalaması (Pharmaceuticals)	2.4%
Analist tahmini (AXSM) (3 yıla kadar)	0%

Önemli Temettü: AXSM şirketinin temettü getirisi, şirketin yakın zamanda herhangi bir ödeme bildirmemesi nedeniyle, temettü ödeyenlerin en alttaki %25'lik dilimine göre değerlendirilemiyor.

Yüksek Temettü: Şirketin yakın zamanda herhangi bir ödeme bildirmemesi nedeniyle, AXSM şirketinin temettü getirisi, temettü ödeyenlerin en üst %25'ine göre değerlendirilemiyor.

Hissedarlara Ödenen Kazanç

Kazanç Kapsamı: AXSM şirketinin temettü ödemelerinin kazançlarla karşılanıp karşılanmadığını belirlemek için ödeme oranını hesaplamak üzere yeterli veri yok.

Hissedarlara Nakit Ödeme

Nakit Akışı Kapsamı: AXSM herhangi bir ödeme bildirmediğinden temettülerin sürdürülebilirliği hesaplanamıyor.

Axsome Therapeutics Temettüler ve Geri Alımlar

Temettü kriter kontrolleri 0/6

Anahtar bilgiler

Son temettü ve geri alım güncellemeleri

Recent updates

Axsome: AXS-07 And Its Upcoming Second PDUFA

Axsome Therapeutics, Inc. to Report Q3, 2024 Results on Nov 12, 2024

Getting In Cheap On Axsome Therapeutics, Inc. (NASDAQ:AXSM) Might Be Difficult

Axsome Therapeutics Announces FDA Acceptance of NDA Resubmission for AXS-07 for the Acute Treatment of Migraine

Axsome Therapeutics Reaches Agreement to Dismiss Sunosi (Solriamfetol) Patent Litigation with Sandoz Inc

Axsome's Auvelity: High Hopes Meet Hefty Bills (Rating Downgrade)

Axsome Therapeutics: Lots Of Moving Parts

Axsome Therapeutics, Inc. to Report Q2, 2024 Results on Aug 05, 2024

Health Check: How Prudently Does Axsome Therapeutics (NASDAQ:AXSM) Use Debt?

Axsome Therapeutics, Inc. Settles Sunosi (solriamfetol) Patent Litigation with Unichem Laboratories Ltd

Consensus EPS estimates fall by 25%

Why Axsome Therapeutics Is A Promising Stock Pick In CNS Treatments

Axsome Therapeutics, Inc. (NASDAQ:AXSM) First-Quarter Results: Here's What Analysts Are Forecasting For This Year

Forecast breakeven date pushed back to 2026

First quarter 2024 earnings: Revenues exceed analysts expectations while EPS lags behind

Axsome Therapeutics, Inc., Annual General Meeting, Jun 07, 2024

Axsome Therapeutics, Inc.'s (NASDAQ:AXSM) Price In Tune With Revenues

Axsome Therapeutics, Inc. to Report Q1, 2024 Results on May 06, 2024

COO & Secretary exercised options and sold US$1.9m worth of stock

Axsome Therapeutics, Inc. Initiates Engage Phase 3 Trial of Solriamfetol for the Treatment of Binge Eating Disorder

Axsome Therapeutics, Inc. Announces Results of CRESCENDO Narcolepsy Patient Survey Demonstrating Unmet Needs in Treated Narcolepsy Type 1 Patients

Axsome Therapeutics Initiates PARADIGM Phase 3 Trial of Solriamfetol for the Treatment of Major Depressive Disorder

Does Axsome Therapeutics (NASDAQ:AXSM) Have A Healthy Balance Sheet?

Independent Lead Director notifies of intention to sell stock

Consensus EPS estimates fall by 21%

Axsome: Unpacking Auvelity's First-Year Market Dynamics And Economic Challenges

Full year 2023 earnings: EPS misses analyst expectations

Axsome Therapeutics, Inc. to Report Q4, 2023 Results on Feb 20, 2024

Axsome Therapeutics, Inc.'s (NASDAQ:AXSM) P/S Is Still On The Mark Following 27% Share Price Bounce

Is Axsome Therapeutics (NASDAQ:AXSM) Using Debt In A Risky Way?

Rosen Law Firm Announces the Reopening of the Lead Plaintiff Appointment Process in a Class Action Against Axsome Therapeutics, Inc. and Certain Officers

Third quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Axsome Therapeutics, Inc. Presents Results of the Accord Trial of AXS-05 in Alzheimer's Disease Agitation at the Clinical Trials on Alzheimer's Disease Agitation at its Clinical Trials on Alzheimer's Disease 2023 Conference

Axsome Therapeutics Appoints Sue Mahony to Its Board of Directors

Axsome Therapeutics Appoints Sue Mahony to Its Board of Directors

Axsome Therapeutics, Inc. to Report Q3, 2023 Results on Nov 06, 2023

Independent Director notifies of intention to sell stock

Is Axsome Therapeutics (NASDAQ:AXSM) Using Debt In A Risky Way?

Consensus EPS estimates fall by 12%, revenue upgraded

Axsome Therapeutics, Inc.'s (NASDAQ:AXSM) Price In Tune With Revenues

Axsome Therapeutics, Inc. to Report Q2, 2023 Results on Aug 07, 2023

Axsome Therapeutics Initiates Focus Phase 3 Trial of Solriamfetol for the Treatment of Attention Deficit Hyperactivity Disorder (Adhd) in Adults

Axsome Therapeutics, Inc. has completed a Follow-on Equity Offering in the amount of $225 million.

Axsome Therapeutics, Inc. has completed a Follow-on Equity Offering in the amount of $225 million.

Axsome Therapeutics, Inc. to Present New Sunosi Data at Sleep 2023

Consensus revenue estimates increase by 45%

Upgrade: Analysts Just Made A Dazzling Increase To Their Axsome Therapeutics, Inc. (NASDAQ:AXSM) Forecasts

Consensus EPS estimates fall by 27%

Earnings Update: Axsome Therapeutics, Inc. (NASDAQ:AXSM) Just Reported Its Yearly Results And Analysts Are Updating Their Forecasts

Is Axsome Therapeutics (NASDAQ:AXSM) Using Debt Sensibly?

Axsome Therapeutics, Inc. to Report Q4, 2022 Results on Feb 27, 2023

Forecast to breakeven in 2025

Axsome Therapeutics Presents New Data from the Evolve Open-Label Trial Demonstrating Effects of Auvelity® on Cognitive and Physical Functioning in Patients with Major Depressive Disorder At the American College of Neuropsychopharmacology (Acnp) 2022 Annual Meeting

Price target increased to US$109

Axsome Therapeutics, Inc. Announces AXS-05 Achieves Primary Endpoint in the ACCORD Phase 3 Trial in Alzheimer’s Disease Agitation

Insufficient new directors

Is Axsome Therapeutics (NASDAQ:AXSM) Weighed On By Its Debt Load?

Axsome Therapeutics, Inc. to Report Q3, 2022 Results on Nov 07, 2022

Axsome Therapeutics, Inc. Announces Availability of Auvelity, the First and Only Oral NMDA Receptor Antagonist for the Treatment of Major Depressive Disorder in Adults

No longer forecast to breakeven

Axsome Therapeutics: Clear Path Ahead For AXS07

Axsome Therapeutics, Inc. Announces Sunosi® (Solriamfetol) Meets Primary Endpoint Demonstrating Improvement in Cognitive Function in the Sharp Trial in Cognitively Impaired Patients with Excessive Daytime Sleepiness Associated with Obstructive Sleep Apnea

Axsome Therapeutics, Inc. Announces Plans to Resubmit AXS-07 NDA Based on Successful FDA Type A Meeting

Axsome to resubmit marketing application for migraine therapy in Q3 2023

Axsome: In The Middle Of Uncertainty Is Your Biggest Opportunity

Axsome Therapeutics, Inc. Initiates ADVANCE-2 Phase 3 Trial of AXS-05 in Alzheimer’s Disease Agitation

Forecast to breakeven in 2024

Axsome Therapeutics Announces Publication of Post-hoc Analysis of Sunosi® Effect on Excessive Daytime Sleepiness in Narcolepsy or Obstructive Sleep Apnea Patients with a History of Depression in the Journal of Psychiatric Research

Axsome Therapeutics Initiates EMERGE Phase 3 Open-Label Trial of AXS-07 for the Acute Treatment of Migraine in Adults with a Prior Inadequate Response to an Oral CGRP Inhibitor

Axsome begins enrolling in late-stage study of migraine drug AXS-07

Price target increased to US$92.93

Axsome Therapeutics Announces FDA Approval of AUVELITY(TM), the First and Only Oral NMDA Receptor Antagonist for the Treatment of Major Depressive Disorder in Adults

Axsome gains 19% as FDA approves depression therapy

No longer forecast to breakeven

Axsome Therapeutics Q2 2022 Earnings Preview